{% extends "layout.html" %}
  
{% block title %}Entrepreneurship{% endblock %}
{% block lead %}The entrepreneurship prize recognizes exceptional effort to build a business case and commercialize an iGEM project.{% endblock %}

{% block page_content %}


<div class="page-container">
  <aside class="sidebar">
      <ul class="sidebar-nav">
          <li><a href="#problema" class="active">Problem & Market Need</a></li>
          <li><a href="#pain-points">Market Pain Points and Stakeholders</a></li>
            <ul class="sidebar-subnav">
              <li><a href="#market-sizing">Market Sizing</a></li>
              <li><a href="#key-value">Key Value Differentiator</a></li>
          </ul>
          <li><a href="#competencia">Competitive Landscape</a></li>
          <li><a href="#ip-rd">IP & R&D Foundation</a></li>
          <li><a href="#tadpole">TADPOLE: R&D Engine and Open-Source Contribution</a></li>
          <li><a href="#comercialitzacio">Commercialization Strategy</a></li>
          <ul class="sidebar-subnav">
              <li><a href="#business-canvas">Business Model Canvas</a></li>
              <li><a href="#business-summary">Business Model Summary</a></li>
          </ul>
          <li><a href="#escalabilitat">Scalability & Growth Plan</a></li>
          <ul class="sidebar-subnav">
              <li><a href="#scalabillity">Scalability</a></li>
              <li><a href="#roadmap">Roadmap</a></li>
              <li><a href="#ganttchart">Gantt Chart</a></li>
          </ul>
          <li><a href="#swot">SWOT Analysis</a></li>
          <li><a href="#igem-industria">From iGEM to Industry</a></li>
          <ul class="sidebar-subnav">
              <li><a href="#commercial-launchpad">Commercial Launchpad</a></li>
              <li><a href="#three-pillars">Three Pillars of Commercialization</a></li>
              <li><a href="#long-term">Long-Term Vision</a></li>
          </ul>
      </ul>
  </aside>
  
  <div class="page-content">
    <div class="header">
      <!-- TÍTOL PRINCIPAL-->
       <h1 class="page-title">Entrepreneurship</h1>
      <p class="page-desc">Bridging the Gap: SKIPPIT’s Path to Commercial Gene Control</p>
    </div>
    <div class="content"> 
      
      <!-- INICI DE LA INTRODUCCIÓ -->
      <section class="page-intro">
        
        <!-- REQUADRE (CALLOUT) -->
        <div class="card" style="background-color: #FDD8D8; border: 1px solid #F0B0B0; margin-bottom: 20px;">
            <p class="section-text" style="font-weight: 700; color: #A30000;">
                SKIPPIT delivers tunable translational control for multi-protein systems, bridging synthetic biology innovation with market-ready solutions.
            </p>
        </div>

        <p class="section-text" style="text-align: center; margin-top: -10px; margin-bottom: 30px;">
            <b>Adjustable ratios, modular design, high precision.</b>
        </p>
        
        <p class="section-text">
            The <b style="color: #cc0000;">SKIPPIT</b> platform moves beyond academic innovation to address a critical market demand, positioning itself as a high-value, patentable enterprise within the rapidly expanding synthetic biology and gene therapy sectors.
        </p>

        <div class="card" style="margin-bottom: 20px;">
            <p class="section-text" style="color: #000000;">
                Our focus is on solving a persistent problem in biotechnology: the lack of <span style="font-weight: 700; color: #A30000; text-decoration: underline;">precise and rapid control of protein expression</span> in complex biological systems.
            </p>
        </div>
        
        
        <!-- INICI DEL NOU DISSENY PER AL DIAGRAMA WHW (FIGURA 1) -->
        
        <!-- Botó/Enllaç -->
        <div style="text-align: center; margin: 30px auto;">
            <button id="whw-toggle-button" onclick="toggleWHW()" style="color: #CC0000; font-weight: 700; background: none; border: none; cursor: pointer; font-size: 1.2em; text-decoration: underline; padding: 10px 0;">
                SKIPPIT's Business Thesis
            </button>
        </div>

        <!-- CONTINGUT AMAGAT -->
        <div id="whw-image-container" style="display: none; max-width: 700px; margin: 20px auto 40px auto; padding: 0; background-color: #ffffff;">
            <h3 style="text-align: center; color: #CC0000; font-weight: 800; margin-top: 0; margin-bottom: 20px; text-transform: uppercase;">
                Our Business Thesis: Why, How, What
            </h3>
            <figure style="margin: 0; text-align: center;">
                <img 
                    src="https://static.igem.wiki/teams/5622/images/ep/1-whw.webp" 
                    alt="Diagrama conceptual de SKIPPIT: Why, How, What" 
                    style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #ddd; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
                />
                <figcaption style="margin-top: 15px; font-style: italic; color: #444; font-size: 0.9em; font-weight: 500;">
                    Figure 1. The core conceptual framework of SKIPPIT: Problem (Why), Mechanism (How), and Application (What). This defines our market-entry strategy.
                </figcaption>
            </figure>
        </div>
        <!-- FINAL DEL NOU DISSENY PER AL DIAGRAMA WHW (FIGURA 1) -->

      </section>
      <!-- FINAL DE LA INTRODUCCIÓ -->
      
      <!-- INICI DEL BLOC -->
      <style>
          /* Estils generals que estaven al Header Preview */
          /* TÍTOL PRINCIPAL */
          .page-title { font-size: 2.5em; text-align: center; margin-bottom: 40px; } 
          
          .section-title { 
              font-size: 2em; 
              color: #000000; 
              padding-bottom: 5px; 
              margin-top: 50px; 
              margin-bottom: 25px; 
              font-weight: 800;
          }
          
          .subsection-title {
              font-size: 1.5em;
              color: #CC0000;
              border-bottom: 2px solid #FDD8D8;
              padding-bottom: 5px;
              margin-top: 35px;
              margin-bottom: 20px;
              font-weight: 700;
          }
          
          .section-text { font-size: 1.1em; line-height: 1.6; margin-bottom: 15px; }
          .table { width: 100%; border-collapse: collapse; margin-top: 15px; }
          .table th, .table td { border: 1px solid #ddd; padding: 12px; text-align: left; }
          .table th { background-color: #f2f2f2; color: #333; font-weight: 700; }
          
          .problem-solution-grid {
              display: grid;
              grid-template-columns: 1fr 80px 1fr; 
              align-items: center; 
              gap: 0;
              margin: 40px 0;
          }
          .problem-box, .solution-box {
              padding: 30px;
              border-radius: 12px;
              box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
              transition: transform 0.3s;
              height: 100%; 
              background-color: white; 
              border: 1px solid #ddd; 
          }
          .arrow-connector {
              grid-column: 2 / 3;
              text-align: center;
              font-size: 3em;
              color: #CC0000; 
              font-weight: 900;
          }
          .problem-box h2, .solution-box h2 {
              text-align: center;
              font-size: 1.2em;
              font-weight: 800;
              margin-bottom: 20px;
              text-transform: uppercase;
              padding-bottom: 5px;
              border-bottom: 2px solid;
          }
          .problem-box h2 { color: #CC0000; border-color: #CC0000; }
          .solution-box h2 { color: #CC0000; border-color: #CC0000; } 
          .problem-box li, .solution-box li {
              margin-bottom: 15px;
              list-style-type: none;
              position: relative;
              padding-left: 30px;
          }
          .problem-box li::before {
              content: "❌"; 
              position: absolute;
              left: 0;
              color: #CC0000;
              font-size: 1.2em;
              top: 0;
          }
          .solution-box li::before {
              content: "✅"; 
              position: absolute;
              left: 0;
              color: #CC0000;
              font-size: 1.2em;
              top: 0;
          }
          @media (max-width: 768px) {
              .problem-solution-grid {
                  grid-template-columns: 1fr;
                  gap: 30px;
              }
              .arrow-connector {
                  display: none; 
              }
              .problem-box {
                  margin-bottom: 20px;
              }
          }
          .card {
              padding: 20px;
              border-radius: 8px;
              margin-top: 20px;
              margin-bottom: 20px;
              background-color: #f7f7f7; 
              border-left: 5px solid #CC0000;
          }
          .card-title {
              font-size: 1.2em;
              font-weight: 700;
              color: #333;
              margin-top: 0;
              margin-bottom: 10px;
          }
          .page-content ul {
              list-style-type: disc;
              margin-left: 25px;
              padding: 0;
          }
          .page-content ul li {
              margin-bottom: 10px;
          }
          .page-content img {
              max-width: 100%;
              height: auto;
          }

          /* DIAGRAMA DE MARKET SIZING */
          .market-diagram {
              display: grid;
              grid-template-columns: 1fr 1fr;
              grid-template-rows: auto auto auto; 
              gap: 20px;
              margin: 40px 0;
              position: relative;
              padding: 20px 0;
          }

          .market-node {
              padding: 20px;
              border-radius: 12px;
              text-align: center;
              box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
              transition: all 0.3s ease;
              border: 1px solid #ddd;
              min-height: 150px;
              display: flex;
              flex-direction: column;
              justify-content: flex-start;
              cursor: default; 
          }
          
          .center-node {
              grid-column: 1 / 3;
              background-color: #CC0000;
              color: white;
              padding: 40px 20px;
              border-radius: 50%;
              width: 250px; 
              height: 250px;
              margin: 0 auto;
              display: flex;
              align-items: center; 
              justify-content: center; 
              text-align: center; 
              font-size: 1.8em;
              font-weight: 900;
              text-transform: uppercase;
              border: 5px solid #FDD8D8;
              box-shadow: 0 8px 15px rgba(204, 0, 0, 0.3);
              z-index: 10;
              grid-row: 2 / 3; 
          }
          
          /* Estils dels nodes de les branques */
          .branch-node {
              background-color: #ffffff;
              border-left: 5px solid #CC0000;
              text-align: left;
              transition: all 0.3s ease;
          }
          
          .branch-node:hover {
              transform: translateY(-5px);
              box-shadow: 0 8px 20px rgba(0, 0, 0, 0.15);
              background-color: #fffafb;
          }

          .branch-node h3 {
              color: #CC0000;
              font-size: 1.3em;
              font-weight: 800;
              margin-top: 0;
              padding-bottom: 5px;
              border-bottom: 2px solid #FDD8D8;
              margin-bottom: 10px;
          }
          
          .branch-node ul {
              list-style-type: none;
              padding: 0;
              margin: 0;
          }
          .branch-node ul li {
              margin-bottom: 8px;
              position: relative;
              padding-left: 15px;
              font-size: 1em;
              line-height: 1.4;
          }
          .branch-node ul li::before {
              content: "•";
              color: #CC0000;
              font-weight: bold;
              display: inline-block;
              width: 1em;
              margin-left: -1em;
          }

          #branch-1 { grid-area: 1 / 1 / 2 / 2; } /* Top Left */
          #branch-2 { grid-area: 1 / 2 / 2 / 3; } /* Top Right */
          #branch-3 { grid-area: 3 / 1 / 4 / 2; } /* Bottom Left */
          #branch-4 { grid-area: 3 / 2 / 4 / 3; } /* Bottom Right */

          @media (max-width: 900px) {
              .center-node {
                  width: 200px;
                  height: 200px;
                  font-size: 1.5em;
              }
          }

          @media (max-width: 768px) {
              .market-diagram {
                  grid-template-columns: 1fr;
                  grid-template-rows: auto;
                  padding: 10px;
              }
              .center-node {
                  grid-column: 1 / 2;
                  margin-bottom: 20px;
                  width: 180px;
                  height: 180px;
                  font-size: 1.3em;
                  grid-row: auto; 
              }
              .branch-node {
                  grid-column: 1 / 2;
                  grid-row: auto;
              }
              
              .center-node { order: 1; }
              #branch-1 { order: 2; } 
              #branch-2 { order: 3; } 
              #branch-3 { order: 4; } 
              #branch-4 { order: 5; } 
          }
          
        
        .market-buttons {
            display: flex;
            justify-content: space-around;
            gap: 10px;
            margin-bottom: 20px;
            flex-wrap: wrap; 
        }

        .market-button {
            flex: 1;
            padding: 12px 15px;
            font-size: 1em;
            font-weight: 700;
            color: #CC0000;
            background-color: #ffffff;
            border: 2px solid #CC0000;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.3s ease;
            text-transform: uppercase;
        }
        
        .market-button:hover:not(.active) {
            background-color: #FDD8D8;
            box-shadow: 0 2px 5px rgba(0, 0, 0, 0.1);
        }

        .market-button.active {
            color: white;
            background-color: #CC0000;
            box-shadow: 0 4px 10px rgba(204, 0, 0, 0.4);
            transform: translateY(-2px);
        }
        
        .market-content {
            padding: 15px;
            border: 1px dashed #FDD8D8;
            border-radius: 8px;
            background-color: #fff;
            min-height: 100px;
            text-align: left;
        }

        .market-content h4 {
            font-size: 1.1em;
            font-weight: 800;
            color: #333;
            margin-top: 0;
            margin-bottom: 5px;
        }
        
        .market-content p {
            margin-bottom: 10px;
            font-size: 0.95em;
        }
        
        .market-value {
            font-size: 1.3em;
            font-weight: 900;
            color: #CC0000;
            margin-top: 10px;
        }
        
        /* --- COMPETITIVE LANDSCAPE --- */
        .competitive-comparison {
            display: grid;
            grid-template-columns: 1fr 1fr; /* Two main columns */
            gap: 20px 40px; /* Vertical and horizontal gap */
            margin: 40px 0;
            position: relative;
            padding: 20px;
            border: 1px solid #ddd;
            border-radius: 12px;
            background-color: #fcfcfc;
        }

        /* Central Divider Line*/
        .competitive-comparison::after {
            content: '';
            position: absolute;
            top: 0;
            bottom: 0;
            left: 50%;
            transform: translateX(-50%);
            width: 2px;
            background-color: #FDD8D8; 
            z-index: 1;
        }

        .category-title-bar {
            grid-column: 1 / 3; 
            text-align: center;
            background-color: #FDD8D8;
            color: #CC0000;
            padding: 12px;
            font-size: 1.2em;
            font-weight: 800;
            margin: 0;
            border-radius: 8px;
            margin-bottom: 10px;
            position: relative;
            z-index: 5;
            border: 1px solid #CC0000;
        }

        .comparison-block {
            padding: 15px;
            border-radius: 8px;
            background-color: #fff;
            position: relative;
            z-index: 2;
            min-height: 120px; 

            display: flex; 
            flex-direction: column;
            justify-content: center; 
            align-items: center; 
            text-align: center; 
        }

        .competitor-list {
            border: 1px solid #ddd;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.05);
        }

        .skippit-advantage {
            border: 2px solid #CC0000; 
            background-color: #fffafb;
            box-shadow: 0 4px 8px rgba(204, 0, 0, 0.1);
        }
        
        .comparison-block h4 {
            font-size: 1.1em;
            font-weight: 800;
            color: #CC0000;
            margin-top: 0;
            margin-bottom: 10px;
        }
        
        .comparison-block p {
            font-size: 0.95em;
            line-height: 1.5;
        }

        .competitive-comparison ul {
            list-style: none;
            padding: 0;
            margin: 0;
            text-align: center;
        }
        .competitive-comparison li {
            margin-bottom: 8px;
            font-size: 0.95em;
        }
        .competitive-comparison li::before {
            content: none;
        }
        
        @media (max-width: 768px) {
            .competitive-comparison {
                grid-template-columns: 1fr;
                gap: 20px;
                padding: 10px;
            }
            .competitive-comparison::after {
                display: none; /
            }
            .category-title-bar {
                grid-column: 1 / 2;
                margin-top: 10px;
                margin-bottom: 0;
            }
            .competitor-list, .skippit-advantage {
                grid-column: 1 / 2;
                min-height: auto;
            }
            .competitor-list { margin-bottom: 10px; }
        }
        
        /* --- CONTINGUT (IP i GANTT) --- */
        
        #detailedIPContent, #detailedGanttContent {
            transition: max-height 0.5s ease-in-out, opacity 0.4s ease-in-out;
            overflow: hidden;
            max-height: 0;
            opacity: 0;
        }
        #detailedIPContent.open, #detailedGanttContent.open {
            max-height: 2000px; 
            opacity: 1;
            margin-top: 1.5rem;
        }
        .ip-toggle-button {
            transition: all 0.3s ease;
            background-color: #CC0000; 
            color: white;
            font-weight: 700;
            border-radius: 8px;
            padding: 10px 20px;
            border: none;
            cursor: pointer;
            box-shadow: 0 4px 6px -1px rgba(204, 0, 0, 0.3), 0 2px 4px -2px rgba(204, 0, 0, 0.2);
            display: block; 
            margin: 20px auto; 
        }
        .ip-toggle-button:hover {
            transform: translateY(-1px);
            background-color: #A30000; 
        }
        
        .pillars-table {
            width: 100%;
            border-collapse: separate; 
            border-spacing: 0 10px; 
            margin-top: 20px;
        }
        .pillars-table th, .pillars-table td {
            padding: 15px;
            text-align: left;
            border: 1px solid #ddd;
            background-color: white; 
            vertical-align: top; 
        }
        .pillars-table th {
            background-color: #CC0000;
            color: white;
            font-weight: 800;
            text-transform: uppercase;
            border: none;
            padding: 10px 15px;
        }
        .pillars-table tr:first-child th:first-child { border-top-left-radius: 8px; }
        .pillars-table tr:first-child th:last-child { border-top-right-radius: 8px; }
        
        .pillar-row td {
            border: 2px solid #FDD8D8;
            border-radius: 8px;
            box-shadow: 0 2px 5px rgba(0, 0, 0, 0.05);
        }
        .pillar-row:hover td {
            background-color: #fffafb;
        }
        .pillar-row td:first-child {
            font-weight: 700;
            color: #CC0000;
            background-color: #FDD8D8;
            width: 25%;
            font-size: 1.1em;
            border-top-left-radius: 8px;
            border-bottom-left-radius: 8px;
            border-right: none;
        }
        .pillar-row td:nth-child(2) {
            width: 15%;
            font-weight: 600;
            color: #333;
        }
        .pillar-row td:last-child {
            border-top-right-radius: 8px;
            border-bottom-right-radius: 8px;
        }
        
        @media (max-width: 768px) {
            .pillars-table, .pillars-table tbody, .pillars-table tr, .pillars-table td {
                display: block; 
                width: 100%;
            }
            .pillars-table thead { display: none; } 
            .pillar-row {
                margin-bottom: 20px;
                display: flex;
                flex-direction: column;
            }
            .pillar-row td {
                border-radius: 0 !important;
                border: 1px solid #ddd;
                box-shadow: none;
            }
            .pillar-row td:first-child {
                border-top-left-radius: 8px !important;
                border-top-right-radius: 8px !important;
                border-bottom: 2px solid #CC0000;
                width: 100%;
            }
            .pillar-row td:last-child {
                border-bottom-left-radius: 8px !important;
                border-bottom-right-radius: 8px !important;
            }
            .pillar-row td:nth-child(2) {
                 border-top: none; 
            }
            .pillar-row td:first-child, .pillar-row td:nth-child(2) { 
                width: 100%; 
            }

        }
      </style>
      
      
      <!-- SECCIONS D'EMPRESA: SECCIÓ 1 -->
      
      <section id="problema">
        <!-- Títol de la Secció 1: SENSE SUBRATLLAT -->
        <h1 class="section-title">
            Problem & Market Need
        </h1>

        <!-- DISSENY VISUAL DE PROBLEMA VS SOLUCIÓ AMB FLETXA -->
        <div class="problem-solution-grid">
            
            <!-- PROBLEMA: Limitacions del Control Transcripcional (Left) -->
            <div class="problem-box">
                <h2>The Problem: The Limits of Transcriptional Control</h2>
                <!-- TEXT AMB NEGRETA I VERMELL -->
                <p class="section-text" style="text-align: left; margin-bottom: 20px;">
                    The biotech industry relies heavily on <b style="color: #CC0000;">transcriptional control methods</b> (e.g., inducible promoters, CRISPRi, RNAi). As highlighted in our research, these methods are often flawed:
                </p>
                <!-- IMATGE -->
                <figure style="margin: 15px auto; text-align: center;">
                    <img 
                        src="https://static.igem.wiki/teams/5622/images/ep/2-the-problem.webp" 
                        alt="Diagram illustrating the flaws of Transcriptional Control and its lack of speed" 
                        style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000;"
                    />
                    <figcaption style="font-style: italic; color: #666; font-size: 0.8em; margin-top: 5px;">
                        Figure 2. Conceptual Diagram: Limitations of Transcription (Slow, Leaky, Fixed Ratios)
                    </figcaption>
                </figure>
            </div>
            
            <div class="arrow-connector">
                &rarr;
            </div>

            <!-- SOLUCIÓ: Avantatges de SKIPPIT al Control Transaccional (Right) -->
            <div class="solution-box">
                <!-- NOU TÍTOL DE SOLUCIÓ -->
                <h2>The Solution: Translational Precision</h2>
                <!-- TEXT DE SOLUCIÓ -->
                <p class="section-text" style="text-align: left; margin-bottom: 25px;">
                    <!-- CANVI: SKIPPIT a Vermell -->
                    <b style="color: #CC0000;">SKIPPIT</b> introduces a disruptive solution through translational control via novel RNA switches based on <b style="color: #CC0000;">Stop Codon Readthrough (SCR)</b>.
                    <br><br>
                    Our proprietary innovation lies in the development of <b style="color: #CC0000;">unique SCR sequences and designed constructs</b> that act as molecular rheostats. These elements allow <b style="color: #CC0000;">Dual, Differential Protein Expression</b> from a single mRNA transcript, achieving a level of precision and modularity unmatched in current market solutions.
                </p>
                
                <!-- TAULA DE COMPARACIÓ -->
                <p class="section-text" style="font-weight: 700; margin-bottom: 10px; margin-top: 30px; border-bottom: 1px solid #CC0000; padding-bottom: 5px; color: #CC0000;">
                    SKIPPIT's Core Competitive Features
                </p>
                <table class="table">
                    <thead>
                        <tr>
                            <th>Feature</th>
                            <th>Description</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td style="font-weight: 600; width: 30%;">Adjustable Expression Ratios</td>
                            <td>The ability to “choose your own expression ratio” (e.g., Protein 1 at 50% and Protein 2 at 10%). No commercial system offers this degree of translational control.</td>
                        </tr>
                        <tr>
                            <td style="font-weight: 600; width: 30%;">Modular Design</td>
                            <td>The SCRs and constructs are compatible across systems, simplifying design for researchers and industry partners.</td>
                        </tr>
                        <tr>
                            <td style="font-weight: 600; width: 30%;">High Precision</td>
                            <td>Wet-lab results demonstrate consistent readthrough levels up to 14%, enabling fine-tuned regulation of complex pathways.</td>
                        </tr>
                    </tbody>
                </table>
                <figcaption style="margin-top: 10px; font-style: italic; color: #666; font-size: 0.8em; text-align: center;">
                    Table 1. Key features of the SKIPPIT platform and their value proposition to the market.
                </figcaption>
                <!-- FI DE LA TAULA DE COMPARACIÓ -->
            </div>
            
        </div>
        
      </section>
      
      <!-- INICI DE LES SECCIONS D'EMPRESA: SECCIÓ 2 -->
      
      <section id="pain-points">
        <h1 class="section-title" style="color: #000000;">
Market Pain Points and Stakeholders        </h1>
        
        <figure style="margin: 15px auto 30px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/3-market-and-stakeholders.webp" 
                alt="Diagram showing SKIPPIT's target market segments and key stakeholders" 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #ddd; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 3. The target market segments for SKIPPIT: Synthetic Biology, Industrial Biotechnology, and Gene Therapy, and their respective pain points.
            </figcaption>
        </figure>

        <!-- SUBSECCIÓ 2.1: MARKET SIZING -->
        <h2 id="market-sizing" class="section-subtitle">Market Sizing</h2>
        

        <div class="market-diagram">
            
            <!-- NODE CENTRAL (Market Opportunity) -->
            <div class="center-node">
                Market Opportunity
            </div>

            <!-- BRANCA 1: GLOBAL MARKET -->
            <div id="branch-1" class="market-node branch-node">
                <h3>Global Market</h3>
                <ul>
                    <li>Synthetic Biology, RNA Therapeutics.</li>
                    <li>Target: To become the underlying technology for fundamental multi-protein expression.</li>
                </ul>
            </div>

            <!-- BRANCA 2: TADPOLE Niche (R&D Engine) -->
            <div id="branch-2" class="market-node branch-node">
                <h3>TADPOLE Niche</h3>
                <ul>
                    <li>RNA switch design, Educational and open-access focus.</li>
                    <li>Target: Establish community adoption and viral marketing of the core technology.</li>
                </ul>
            </div>

            <!-- BRANCA 3: MARKET SIZE (TAM, SAM, SOM) - NOU BLOC INTERACTIU  -->
            <div id="branch-3" class="market-node branch-node">
                <h3>Market Size</h3>
                
                <div class="market-buttons">
                    <button class="market-button active" id="btn-tam" onclick="displayMarketSize('tam')">TAM</button>
                    <button class="market-button" id="btn-sam" onclick="displayMarketSize('sam')">SAM</button>
                    <button class="market-button" id="btn-som" onclick="displayMarketSize('som')">SOM</button>
                </div>

                <div id="market-tam" class="market-content">
                    <h4>Total Addressable Market (TAM)</h4>
                    <p>Global Synthetic Biology and Genetic Engineering Tools Market. Represents the totality of demand for products and services in our sector.</p>
                    <p class="market-value">Estimated Market (2025-2030): $15−20 Billion USD</p>
                </div>
                
                <div id="market-sam" class="market-content" style="display: none;">
                    <h4>Serviceable Available Market (SAM)</h4>
                    <p>Segment using translational control (IRES, 2A Peptides) or requiring multi-gene vector optimization (Biopharma R&D, Gene Therapy). Market where SKIPPIT is directly applicable.</p>
                    <p class="market-value">Estimated Market (2025-2030): $2.5−4 Billion USD</p>
                </div>
                
                <div id="market-som" class="market-content" style="display: none;">
                    <h4>Serviceable Obtainable Market (SOM)</h4>
                    <p>Our target segment in the first 3 years: Academic SynBio Labs and Biotech Startups (US/EU) requiring novel, patent-free parts for research/preclinical development.</p>
                    <p class="market-value">Estimated Market (First 3 Years): $50−100 Million USD</p>
                </div>

            </div>
            <!-- FI NOU BLOC INTERACTIU -->

            <!-- BRANCA 4: PRIMARY MISSION AND PURPOSE (MODIFICADA) -->
            <div id="branch-4" class="market-node branch-node">
                <h3>Primary Mission and Purpose</h3>
                <ul>
                    <li>Education focus, Market positioning.</li>
                    <li>Purpose: To decouple multi-protein expression from slow, costly transcriptional methods.</li>
                </ul>
            </div>

        </div>
        <!-- FINAL NOU DISSENY MARKET SIZING -->

        <!-- SUBSECCIÓ 2.2: KEY VALUE DIFFERENTIATOR  -->
        <h2 id="key-value"class="section-subtitle">Key Value Differentiator</h2>
        
        <p class="section-text">
            <span style="color: #CC0000; font-weight: 700;">SKIPPIT</span>’s strength lies in transforming a complex molecular process into a <span style="color: #CC0000; font-weight: 700;">simple, tunable, and scalable solution</span> for precise protein expression.
            <br><br>
            Where existing tools stop at transcription, SKIPPIT redefines control <span style="color: #CC0000; font-weight: 700;">at the translational level</span>: faster, cleaner, and patentable.
        </p>
        
        <figure style="margin: 15px auto 30px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/5-key-value-differentiator.webp" 
                alt="Diagram showing SKIPPIT's key value differentiator: speed, precision, and tunability versus existing methods." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 4. Visualizing SKIPPIT's core value: moving control from the transcriptional level (slow) to the translational level (fast and tunable).
            </figcaption>
        </figure>

      </section>
      
      <!-- INICI DE LA SECCIÓ 3: COMPETITIVE LANDSCAPE -->
      <section id="competencia">
        <h1 class="section-title">
            Competitive Landscape
        </h1>
        
        <p class="section-text">
            <b style="color: #CC0000;">SKIPPIT</b> competes against existing co-expression tools by addressing the uneven co-expression problem through <b style="color: #CC0000;">precise translational control</b>.
        </p>
        
        <!-- ESTRUCTURA DE COMPARACIÓ COMPETITIVA (Visual Grid) -->
        <div class="competitive-comparison">
            
            <!-- CAPÇALERA: COMPARISON (COLUMN 1) vs. SKIPPIT ADVANTAGE (COLUMN 2) -->
            <div style="grid-column: 1 / 3; font-weight: 800; color: #333; text-align: center; font-size: 1.1em; border-bottom: 2px solid #CC0000; padding-bottom: 5px;">
                EXISTING SOLUTIONS VS. SKIPPIT's ADVANTAGE
            </div>
            
            <!-- CATEGORIA 1: TRANSCRIPTIONAL -->
            <h3 class="category-title-bar">Transcriptional Control Rivals</h3>
            
            <!-- COMPETITORS TRANSCRIPTIONAL (LEFT) -->
            <div class="comparison-block competitor-list">
                <h4>Competitor Examples</h4>
                <!-- UL CENTRAT -->
                <ul>
                    <li>Inducible Promoters (Tet-On/Off)</li>
                    <li>Tandem Promoters</li>
                </ul>
            </div>
            
            <!-- AVANTATGE SKIPPIT (RIGHT) -->
            <div class="comparison-block skippit-advantage">
                <h4>SKIPPIT's Advantage</h4>
                <!-- P CENTRAT -->
                <p>
                    <b style="color: #CC0000;">Superior Kinetics & Modularity:</b> SKIPPIT regulates post-transcriptionally, ensuring faster responses and avoiding promoter interference.
                </p>
            </div>
            
            <!-- CATEGORIA 2: TRANSLATIONAL -->
            <h3 class="category-title-bar">Translational Control Rivals</h3>
            
            <!-- COMPETITORS TRANSLATIONAL (LEFT) -->
            <div class="comparison-block competitor-list">
                <h4>Competitor Examples</h4>
                <!-- UL CENTRAT -->
                <ul>
                    <li>IRES (Internal Ribosome Entry Sites)</li>
                    <li>2A Self-Cleaving Peptides</li>
                </ul>
            </div>
            
            <!-- AVANTATGE SKIPPIT (RIGHT) -->
            <div class="comparison-block skippit-advantage">
                <h4>SKIPPIT's Advantage</h4>
                <p>
                    <b style="color: #CC0000;">Differential & Defined Ratios:</b> 2A peptides yield near-1:1 ratios, while SKIPPIT enables adjustable, pre-determined expression levels. IRES performance remains unpredictable and context-dependent.
                </p>
            </div>
        </div>
        
        <p class="section-text" style="font-weight: 600; text-align: center;">
            <b style="color: #CC0000;">SKIPPIT</b> provides a unique solution for researchers and companies requiring precise translational control in multi-component systems, a feature absent from current market standards.
        </p>

      </section>
      
      <!-- SECCIÓ 4: IP & R&D FOUNDATION -->
      <section id="ip-rd">
        <h1 class="section-title">
            IP & R&D Foundation
        </h1>
        
        <p class="section-text">
            Our intellectual property is built upon rigorous research and development cycles that resulted in unique parts and a proprietary design method, ensuring the project's <b style="color: #CC0000; font-weight: 800;">patentability</b>. The parts we developed and characterized are <b style="color: #CC0000; font-weight: 800;">not published on iGEM</b>, maintaining their novelty and commercial exclusivity.
        </p>
        
        <figure style="margin: 30px auto 10px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/6-ip.webp" 
                alt="Diagram showing SKIPPIT's Intellectual Property Strategy, focusing on novel parts and proprietary design methods." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 5. SKIPPIT's Intellectual Property Strategy, focusing on novel parts and proprietary design methods.
            </figcaption>
        </figure>
        
        <button id="ip-toggle-button" onclick="toggleIPContent()"
                class="ip-toggle-button">
            Llegeix-ne més sobre els Actius Patentables...
        </button>

        <div id="detailedIPContent">
            <!-- SECCIÓ A: Patentable Assets -->
            <h2 class="subsection-title">A. Patentable Assets</h2>
                
            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">Patent 1 — The Product (SCR Sequences & Constructs)</div>
                <p class="section-text text-sm">The specific, novel DNA/RNA SCR sequences and linkers we developed confer precise, differential readthrough levels. Our work on fusing elements, validated by the successful functionality of our linkers in cell-free systems, establishes the viability of these proprietary parts.</p>
            </div>

            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">Patent 2 — The Method (Use of SCR)</div>
                <p class="section-text text-sm">A method for achieving specific, pre-determined differential expression ratios between two proteins using our proprietary SCR elements. This methodology defines SKIPPIT’s translational control precision and its scalability for both research and therapeutic applications.</p>
            </div>

            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">Patent 3 — The Platform (TADPOLE, The R&D Engine)</div>
                <p class="section-text text-sm">Our proprietary automated computational methods, developed during the SCR-D structure prediction cycle, rapidly analyze and design functional RNA elements. This R&D tool represents the engine that generates new, patentable SCRs, forming the foundation of SKIPPIT’s competitive advantage.</p>
            </div>
            
            <!-- SECCIÓ B: Value Derived from the DBTL Cycle -->
            <h2 class="subsection-title">B. Value Derived from the DBTL Cycle</h2>

            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">Failure as IP Driver</div>
                <p class="section-text text-sm">The initial challenges with SCR-D structure prediction (DBTL Cycle 1) led to the creation of a proprietary co-evolutionary analysis tool. This tool is now a patentable R&D asset, ensuring faster and more reliable SCR design.</p>
            </div>

            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">The Pivot to Commercial Advantage</div>
                <p class="section-text text-sm">The shift from the inconsistent SCR-D to the highly structure-dependent SECIS element (DBTL Cycle 2), along with cell-free validation of our linkers, confirmed the functionality of our proprietary products, demonstrating both adaptability and a focus on commercial-grade robustness.</p>
            </div>

            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">Product Expansion</div>
                <p class="section-text text-sm">The development of Aptamer-Controlled SCRs (SECIS-Aptamer fusions) establishes a path for a premium product line offering not only ratio control but also inducible, time-sensitive control, a significant opportunity in precision therapeutics.</p>
            </div>
        </div>
        <!-- Final del Contingut Detallat d'IP -->
        
      </section>
      
    <!-- SECCIÓ 5 -->
<section id="tadpole" style="padding: 0 20px 20px 20px;">

    <!-- Big Dark Callout Container: Uses deep dark gray background and white text -->
    <div style="background-color: #1a1a1a; color: #ffffff; padding: 30px; border-radius: 12px; box-shadow: 0 4px 15px rgba(0, 0, 0, 0.4);">

        <!-- Main Title, adjusted for white text. Red is brightened to pop on dark background. -->
        <h1 class="section-title" style="color: #ffffff; border-bottom: 2px solid #333;">
            <span style="font-weight: 900; color: #FF4444;">TADPOLE</span>: R&D Engine and Open-Source Contribution
        </h1>

        <div style="margin-top: 15px;">
            
            <!-- Column 1: R&D Asset (Commercial Focus) -->
            <div id="tadpole-rd-asset">
                
                <!-- Sub-section Title A -->
                <h2 class="subsection-title" style="color: #ffffff; border-bottom: 1px solid #444;">
                    A. R&D Asset: Intellectual Property & Commercial Advantage
                </h2>
                
                <p class="section-text" style="color: #f0f0f0;">
                    The <span style="font-weight: 700; color: #FF4444;">TADPOLE</span> platform is the proprietary computational backbone driving the rapid design and optimization of SKIPPIT’s SCR sequences. It originated as a solution to the structural prediction challenges identified during DBTL Cycle 1 (SCR-D system) and now serves as both an <span style="font-weight: 700; color: #FF4444;">IP-protected R&D asset</span> and a commercial differentiator.
                </p>

                <!-- Custom Styled Table (Adapting the provided .table aesthetic) -->
                <div style="margin-top: 20px;"> 
                    <h3 style="font-size: 1.3em; font-weight: 800; color: #eee; margin-bottom: 10px; border-bottom: 2px solid #444; padding-bottom: 5px;">
                        <span style="font-weight: 800; color: #FF4444;">TADPOLE</span> Strategic Value
                    </h3>
                    <table class="table" style="border-collapse: separate; border-spacing: 0; border: none; width: 100%;">
                        <thead>
                            <tr style="background-color: #CC0000; color: white;">
                                <!-- Feature column: ~25% -->
                                <th style="border: none; padding: 10px 15px; width: 25%;">Feature</th>
                                <!-- Strategic Value column: WIDER (50%) -->
                                <th style="border: none; padding: 10px 15px; width: 50%;">Strategic Value</th>
                                <!-- IP Connection column: SHORTER (25%) -->
                                <th style="border: none; padding: 10px 15px; width: 25%;">IP Connection</th>
                            </tr>
                        </thead>
                        <tbody>
                            <!-- Adjusted cell backgrounds to maintain readability on dark mode -->
                            <tr class="pillar-row">
                                <td style="font-weight: 700; background-color: #FDD8D8; color: #CC0000; border: 1px solid #CC0000; padding: 8px 15px;">Co-Evolutionary Analysis</td>
                                <td style="background-color: #333; color: #f0f0f0; border: 1px solid #444; padding: 8px 15px; font-weight: 400;">Rapidly identifies highly functional and stable RNA switch sequences.</td>
                                <td style="background-color: #333; color: #f0f0f0; border: 1px solid #444; font-weight: 600; padding: 8px 15px;">Foundation for the Patent of Platform: the core R&D engine.</td>
                            </tr>
                            <tr class="pillar-row">
                                <td style="font-weight: 700; background-color: #FDD8D8; color: #CC0000; border: 1px solid #CC0000; padding: 8px 15px;">Linker Design Pipeline</td>
                                <td style="background-color: #333; color: #f0f0f0; border: 1px solid #444; padding: 8px 15px; font-weight: 400;">Integrates linker generation, OFF-state prediction, and ranking into a cohesive workflow.</td>
                                <td style="background-color: #333; color: #f0f0f0; border: 1px solid #444; font-weight: 600; padding: 8px 15px;">Enables faster, more reliable design of new, patentable SKIPPIT parts, reducing R&D risk.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <!-- Callout Card adjusted for dark mode, using a lighter dark background for separation -->
                <div class="card" style="margin-top: 30px; background-color: #333; border: 1px solid #555; border-radius: 8px; padding: 15px;">
                    <p class="section-text" style="color: #FF4444; margin: 0; font-weight: 400;">
                        <span style="color: #ffffff; font-weight: 700;">Key Takeaway:</span> <span style="color: #FF4444;">TADPOLE</span> accelerates the design of new, highly efficient SCRs, securing SKIPPIT’s competitive edge in translational control technology. Its exclusive use or licensing constitutes a major commercial advantage.
                    </p>
                </div>
            </div>

            <!-- START NEW SECTION B -->
            <div id="tadpole-open-science" style="margin-top: 40px; padding-top: 15px; border-top: 1px solid #333;">
                
                <!-- Sub-section Title B -->
                <h2 class="subsection-title" style="color: #ffffff; border-bottom: 1px solid #444;">
                    B. Open Science & Educational Contribution
                </h2>

                <p class="section-text" style="color: #f0f0f0;">
                    In alignment with iGEM’s principles of collaboration and accessibility, <span style="font-weight: 700; color: #FF4444;">TADPOLE</span> also functions as an open-science initiative and educational tool.
                </p>

                <!-- Bulleted List for Open Science Components -->
                <ul style="list-style-type: disc; margin-left: 20px; color: #f0f0f0;">
                    <li style="margin-bottom: 10px;">
                        <span style="font-weight: 700; color: #fff;">Open-Access Code:</span> 
                        The <span style="font-weight: 700; color: #FF4444;">TADPOLE</span> platform will be released under an open license (e.g., MIT License) to empower future iGEM teams and the academic community.
                    </li>
                    <li style="margin-bottom: 10px;">
                        <span style="font-weight: 700; color: #fff;">Educational Focus:</span> 
                        The platform’s documentation and case studies act as a tutorial on integrating computational and experimental (DBTL) workflows in synthetic biology entrepreneurship.
                    </li>
                </ul>
            </div>
            
            <!-- Disclaimer Section -->
            <div id="tadpole-disclaimer" style="margin-top: 30px; padding: 15px; background-color: #2b2b2b; border: 1px solid #555; border-radius: 8px;">
                <h3 style="font-size: 1.1em; font-weight: 800; color: #FF4444; margin-bottom: 5px;">Disclaimer</h3>
                <p class="section-text" style="color: #ccc; margin: 0; font-style: italic;">
                    <span style="font-weight: 700; color: #FF4444;">TADPOLE</span> is presented as a case study demonstrating SKIPPIT’s R&D and market positioning strategy. While the code is openly accessible, the intellectual property and commercial value remain centered on the sequences and methods developed through the platform (SKIPPIT).
                </p>
            </div>
            <!-- END NEW SECTION B -->
            
        </div>
    </div>
</section>



      <section id="comercialitzacio">
        <h1 class="section-title">
            Commercialization Strategy
        </h1>
        
        <!-- BUSINESS MODEL CANVAS -->
        <h2 id="business-canvas" class="section-subtitle">Business Model Canvas</h2>
        <p class="section-text">
            Our Business Model Canvas highlights how we transform our translational control technology into scalable value for both academia and industry.
        </p>
        <figure style="margin: 30px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/8-business-model-canvas.webp" 
                alt="SKIPPIT's Business Model Canvas outlining key partners, activities, value propositions, customer segments, and revenue streams." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 6. SKIPPIT’s Business Model Canvas: Translating technology into market value.
            </figcaption>
        </figure>
        <!-- FINAL NOU SUBAPARTAT -->
        
        <!-- BUSINESS MODEL SUMMARY -->
        <h2 id="business-summary" class="section-subtitle">Business Model Summary</h2>
        <p class="section-text">
            SKIPPIT’s business model is built around technology licensing and co-development:
        </p>

        <ul style="margin-left: 20px; margin-bottom: 20px;">
            <li><b style="color: #CC0000;">Academic Access:</b> Free-to-use open-source tools (TADPOLE) to promote visibility and validation.</li>
            <li><b style="color: #CC0000;">Commercial Access:</b> Licensing of proprietary SCR libraries and the design engine for use in translational control applications.</li>
            <li><b style="color: #CC0000;">Co-Development:</b> Collaboration with biotech companies to integrate SKIPPIT modules into next-generation gene therapy pipelines.</li>
        </ul>
        <p class="section-text">
            This hybrid model ensures a sustainable balance between open innovation and IP-driven value creation.
        </p>
        <!-- FINAL SUBAPARTAT: BUSINESS MODEL SUMMARY -->
        
      </section>
      
      <section id="escalabilitat">
        <h1 class="section-title">
            Scalability & Growth Plan
        </h1>
        
        <!-- SUBAPARTAT: SCALABILITY -->
        <h2 id="scalabillity" class="section-subtitle">Scalability</h2>
        
        <p class="section-text">
            SKIPPIT scales from the bench to the market: its modular design ensures immediate adoption in academic and startup labs, while its customizable, patentable constructs open a clear path to biopharma integration.
            <br><br>
            This dual scalability (scientific and commercial) positions SKIPPIT as both a research enabler and a future therapeutic platform.
        </p>
        
        <figure style="margin: 30px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/9-scalability.webp" 
                alt="Diagram showing the dual scalability path of SKIPPIT from academic research to biopharma integration." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 7. SKIPPIT's dual scalability path: immediate adoption in research labs and future integration into biopharma therapeutics.
            </figcaption>
        </figure>
        
        <!-- SUBAPARTAT: ROADMAP -->
        <h2 id="roadmap" class="section-subtitle">Roadmap</h2>
        <p class="section-text">
            The Roadmap details the strategic milestones and phases of the project, providing a high-level overview of the short-term and long-term goals for commercialization.
        </p>
        <figure style="margin: 30px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/10-roadmap.webp" 
                alt="Roadmap visualizing SKIPPIT's strategic milestones from R&D to market entry." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 8. Strategic Roadmap outlining the key stages for SKIPPIT’s commercial development.
            </figcaption>
        </figure>

        <!-- SUBAPARTAT: GANTT CHART -->
        <h2 id="ganttchart" class="section-subtitle">Gantt Chart</h2>
        <p class="section-text">
            The Gantt Chart provides a detailed timeline of task execution, crucial for resource allocation and management during the development process.
        </p>
        <figure style="margin: 30px auto 10px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/11-gantt-chart.webp" 
                alt="Gantt chart detailing the project timeline, tasks, and dependencies." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="font-style: italic; color: #666; font-size: 0.9em; margin-top: 10px;">
                Figure 9. Detailed Gantt Chart showing the temporal planning and execution of project tasks.
            </figcaption>
        </figure>

        <!-- LLEGEIX-NE MÉS PER A L'ANÀLISI DEL GANTT CHART -->
        <button id="gantt-toggle-button" onclick="toggleGanttContent()"
                class="ip-toggle-button">
            Read more...
        </button>

        <!-- Contingut Detallat de l'Anàlisi del Gantt Chart (Inicialment Ocult) -->
        <div id="detailedGanttContent">
            
            <h2 class="subsection-title">Strategic Planning Analysis (2025-2030)</h2>
            <p class="section-text">
                The detailed analysis of SKIPPIT's Gantt Chart reveals a phased plan that prioritizes legal protection and external validation before market expansion.
            </p>
            
            <!-- FASE 1: Short-Term Focus (2025-2026) -->
            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">1. Short-Term Focus (2025-2026): Validation and Protection</div>
                <p class="section-text text-sm">This stage correctly prioritizes de-risking the technology and securing its value.
                    <br><br>
                    <b style="color: #CC0000;">Validation & Outreach (2025-2026):</b> Finalizing wet-lab data and presenting at conferences (iGEM & SynBio) in 2025 builds credibility and attracts attention. Seeking academic validation and partnership interest in 2026 is crucial before scaling.
                    <br><br>
                    <b style="color: #CC0000;">IP Filing & Partnerships (2026-2027):</b> Filing provisional patents in 2026 establishes the company's proprietary claims (over the Product, Method, and TADPOLE Platform). Initiating licensing discussions simultaneously shows a commercial intent early on.
                </p>
            </div>

            <!-- FASE 2: Mid-Term Focus (2027-2028) -->
            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">2. Mid-Term Focus (2027-2028): Commercial Proof and Scaling</div>
                <p class="section-text text-sm">This phase moves from internal R&D to external, real-world application, which is necessary for scaling up.
                    <br><br>
                    <b style="color: #CC0000;">IP Protection & Pilot Collaborations (2027):</b> Securing IP protection is essential before implementing SKIPPIT modules in 2-3 biotech R&D pipelines. This serves as crucial pilot commercial validation.
                    <br><br>
                    <b style="color: #CC0000;">Scaling (2028):</b> Demonstrating scalability and reproducibility in 2028 is a necessary milestone to transition from pilot to broad commercial adoption.
                    <br><br>
                    <b style="color: #CC0000;">Product Diversification (2028):</b> The launch of the Aptamer-Controlled SCR (premium product line) in 2028 is a smart strategy to capture a high-value segment (inducible therapeutics) after the core product has been validated.
                </p>
            </div>

            <!-- FASE 3: Long-Term Focus (2029-2030) -->
            <div class="card" style="background-color: #fcfcfc;">
                <div class="card-title" style="color: #CC0000;">3. Long-Term Focus (2029-2030): Market Dominance</div>
                <p class="section-text text-sm">The final stage targets maximal market penetration and establishment as a sector leader.
                    <br><br>
                    <b style="color: #CC0000;">Market Expansion (2029):</b> Extending applications to gene therapy and synthetic cell design is the logical next step, as these are the high-value segments of the SAM (Serviceable Available Market).
                    <br><br>
                    <b style="color: #CC0000;">Industry Standard (2030):</b> Positioning SKIPPIT as an industry standard in 2030 represents the successful realization of the SOM (Serviceable Obtainable Market) and a strong competitive moat.
                </p>
            </div>
            
        </div>
      </section>

      <!-- SECCIÓ SWOT -->
      <section id="swot">
        <h1 class="section-title" style="color: #000000;">
            SWOT Analysis
        </h1>
        <p class="section-text">
            The SWOT analysis (Strengths, Weaknesses, Opportunities, Threats) is a strategic tool used to evaluate the internal and external environment of our project. It helps in identifying the key factors that can influence success.
        </p>
        
        <figure style="margin: 30px auto; text-align: center;">
            <img 
                src="https://static.igem.wiki/teams/5622/images/ep/12-swot.webp" 
                alt="Diagram of SWOT Analysis (Strengths, Weaknesses, Opportunities, Threats) for the SKIPPIT project." 
                style="max-width: 100%; height: auto; border-radius: 4px; border: 1px solid #CC0000; box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);"
            />
            <figcaption style="margin-top: 10px; font-style: italic; color: #666; font-size: 0.9em; text-align: center;">
                Figure 10. Visual representation of SKIPPIT's SWOT Analysis.
            </figcaption>
        </figure>
        
      </section>
      <!-- FI DE LA SECCIÓ SWOT RESTAURADA AMB EL TEXT -->

      <!-- INICI DE LA SECCIÓ: FROM IGEM TO INDUSTRY -->
      <section id="igem-industria">
        <h1 class="section-title" style="color: #000000;">
            From iGEM to Industry
        </h1>
        
        <p class="section-text" style="font-size: 1.1em;">
            <b style="color: #CC0000;">SKIPPIT</b>'s goal is to transition from an iGEM Proof-of-Concept to a market-disrupting biotech enterprise by leveraging our core innovation: <b style="color: #CC0000;">precise, differential translational control</b> via Stop Codon Readthrough (SCR).
        </p>
        
        <h2 id="commercial-launchpad" class="section-subtitle">The Commercial Launchpad: The iGEM Foundation</h2>
        <p class="section-text">
            The immediate strategy after the competition is focused on protecting the technology and seeking entrepreneurial support:
        </p>
        <ul style="margin-left: 20px; margin-bottom: 30px;">
            <li><b style="color: #CC0000;">IP Protection:</b> The plan is to immediately file a Provisional Patent covering two key commercial assets: the novel SCR sequences/constructs (the Product) and the Method for achieving precise differential expression. The value is centered on these proprietary outputs.</li>
            <li><b style="color: #CC0000;">Startup Acceleration:</b> We intend to apply to the iGEM Startups Program for tailored mentorship and access to investor networks.</li>
            <li><b style="color: #CC0000;">Community Goodwill:</b> The TADPOLE computational platform will be released under an open license (e.g., MIT) to empower future iGEM teams and the academic community, establishing SKIPPIT as a leader in open science.</li>
        </ul>

        <h2 id="three-pillars" class="section-subtitle">Three Pillars of Commercialization (2025–2030)</h2>
        <p class="section-text">
            Our commercial strategy is built on a diversified, phased revenue model that monetizes the results of our R&D, not the platform code:
        </p>

        <!-- TAULA DELS TRES PILARS -->
        <table class="pillars-table">
            <thead>
                <tr>
                    <th>Pillar</th>
                    <th>Timeline</th>
                    <th>Description</th>
                </tr>
            </thead>
            <tbody>
                <tr class="pillar-row">
                    <td>Pillar 1: SCR Kit & Library Licensing</td>
                    <td>2025-2027</td>
                    <td>Monetize our foundational IP by selling validated SCR sequences and modular constructs as research kits and non-exclusive licenses.</td>
                </tr>
                <tr class="pillar-row">
                    <td>Pillar 2: TADPOLE Platform Licensing</td>
                    <td>2026+</td>
                    <td>License our proprietary computational engine to large biotech and pharma partners for internal use.</td>
                </tr>
                <tr class="pillar-row">
                    <td>Pillar 3: Premium Inducible Systems</td>
                    <td>2027+</td>
                    <td>Launch a high-value product line of Aptamer-Controlled SCRs, adding ligand-dependent, time-sensitive control to our precision ratio technology.</td>
                </tr>
            </tbody>
        </table>
        
        <figcaption style="margin-top: 10px; font-style: italic; color: #666; font-size: 0.9em; text-align: center;">
            Table 2. The three strategic pillars of SKIPPIT's phased revenue model for 2025–2030.
        </figcaption>

        <h2 id="long-term" class="section-subtitle">Long-Term Vision: The Future of Precision Control</h2>
        <p class="section-text">
            Our long-term vision is to establish our SCR-based technology as one of the industry standards for precise translational control, integral to the design of future gene therapies, engineered cell lines, and sophisticated synthetic biological systems. We are not just selling a tool; we are foundational to the next wave of synthetic biology.
        </p>
      </section>
      <!-- FI DE LA SECCIÓ: FROM IGEM TO INDUSTRY -->

      <section id="bibliografia">
        <h1 class="section-title" style="color: #000000;">
            References
        </h1>
        <p class="section-text">
            Grand View Research. (2024). Synthetic biology market size & share: Industry report 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/synthetic-biology-market
            <br><br>
            Freemont, P. S. (2019). Synthetic biology industry: Data-driven design is creating new opportunities in biotechnology. Emerging Topics in Life Sciences, 3(5), 651–657. https://doi.org/10.1042/ETLS20190062
            <br><br>
            Mordor Intelligence. (2025). Gene expression analysis market size, outlook, trends & competitive landscape. Retrieved from https://www.mordorintelligence.com/industry-reports/global-gene-expression-analysis-market-industry
            <br><br>
            Nature Communications. (2020). Synthetic biology 2020–2030: Six commercially-available products [Editorial]. Nature Communications, 11, Article 6387. https://doi.org/10.1038/s41467-020-20122-2
            <br><br>
            Fortune Business Insights. (2024). Synthetic biology market size, share, growth & forecast. https://www.fortunebusinessinsights.com/synthetic-biology-market-107168
            <br><br>
            Karadzhov, V. (2025). How to create the best SWOT analysis. International Journal of Research and Review, 12(1), 66–74. https://doi.org/10.52403/ijrr.20250110
            <br><br>
            Mordor Intelligence. (2025). Gene therapy market size, growth analysis (2025–2030). https://www.mordorintelligence.com/industry-reports/gene-therapy-market
            <br><br>
            Nova One Advisor. (2023). Gene expression market size & share report, 2033. https://www.novaoneadvisor.com/report/gene-expression-market
            <br><br>
            StatPearls. (2023). SWOT analysis. https://www.ncbi.nlm.nih.gov/books/NBK537302/
            <br><br>
            University Lab Partners. (2020). How to create a business plan. https://www.universitylabpartners.org/blog/how-to-create-a-business-plan
            <br><br>
        </p>
      </section>
      
    </div>
  </div>
</div>

<script>
    /**
     * Toggles the visibility of the "Why, How, What" diagram and updates the button text.
     */
    function toggleWHW() {
        const container = document.getElementById('whw-image-container');
        const button = document.getElementById('whw-toggle-button');
        
        // Textos del botó
        const showText = "SKIPPIT's Business Thesis";
        const hideText = "Hide"; 
        
        // Check if the container is hidden (display: none or empty style)
        if (container.style.display === 'none' || container.style.display === '') {
            container.style.display = 'block';
            button.textContent = hideText;
        } else {
            container.style.display = 'none';
            button.textContent = showText;
        }
    }
    
    /**
     * Toggles the visibility of the TAM/SAM/SOM market sizing content.
     */
    function displayMarketSize(metric) {
        const metrics = ['tam', 'sam', 'som'];

        // 1. Ocultar tot el contingut i desactivar tots els botons
        metrics.forEach(m => {
            const contentDiv = document.getElementById(`market-${m}`);
            const button = document.getElementById(`btn-${m}`);
            
            if (contentDiv) {
                contentDiv.style.display = 'none';
            }
            if (button) {
                button.classList.remove('active');
            }
        });

        // 2. Mostrar el contingut seleccionat i activar el botó
        const selectedContent = document.getElementById(`market-${metric}`);
        const selectedButton = document.getElementById(`btn-${metric}`);

        if (selectedContent) {
            selectedContent.style.display = 'block';
        }
        if (selectedButton) {
            selectedButton.classList.add('active');
        }
    }
    
    /**
     * Toggles the visibility of the detailed IP content.
     */
    function toggleIPContent() {
        const detailedContent = document.getElementById('detailedIPContent');
        const toggleButton = document.getElementById('ip-toggle-button');

        const isOpen = detailedContent.classList.toggle('open');
        
        if (isOpen) {
            // Text original en català
            toggleButton.textContent = 'Hide';
        } else {
            // Text original en català
            toggleButton.textContent = 'Read more...';
        }
    }
    
    /**
     * Toggles the visibility of the detailed Gantt Chart analysis content.
     */
    function toggleGanttContent() {
        const detailedContent = document.getElementById('detailedGanttContent');
        const toggleButton = document.getElementById('gantt-toggle-button');

        const isOpen = detailedContent.classList.toggle('open');
        
        if (isOpen) {
            toggleButton.textContent = 'Hide';
        } else {
            toggleButton.textContent = 'Read more...';
        }
    }

    
    // Assegura que el TAM es mostra per defecte i l'IP/Gantt està tancat quan es carrega la pàgina
    window.onload = function() {
        if (typeof displayMarketSize === 'function') {
            displayMarketSize('tam');
        }
        
        const detailedIPContent = document.getElementById('detailedIPContent');
        if (detailedIPContent) {
            detailedIPContent.classList.remove('open');
        }
        
        const detailedGanttContent = document.getElementById('detailedGanttContent');
        if (detailedGanttContent) {
            detailedGanttContent.classList.remove('open');
        }
    }
</script>
{% endblock %}